WO2007003675A3 - Modele experimental de neuro-inflammation, procede d'obtention et applications - Google Patents

Modele experimental de neuro-inflammation, procede d'obtention et applications Download PDF

Info

Publication number
WO2007003675A3
WO2007003675A3 PCT/ES2006/000387 ES2006000387W WO2007003675A3 WO 2007003675 A3 WO2007003675 A3 WO 2007003675A3 ES 2006000387 W ES2006000387 W ES 2006000387W WO 2007003675 A3 WO2007003675 A3 WO 2007003675A3
Authority
WO
WIPO (PCT)
Prior art keywords
experimental
neuroinflammation
model
applications
obtaining same
Prior art date
Application number
PCT/ES2006/000387
Other languages
English (en)
Spanish (es)
Other versions
WO2007003675A2 (fr
Inventor
Garcia Ana Maria Fernandez
Aleman Ignacio Torres
Hernandez Silvia Fernandez
Original Assignee
Consejo Superior Investigacion
Garcia Ana Maria Fernandez
Aleman Ignacio Torres
Hernandez Silvia Fernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Garcia Ana Maria Fernandez, Aleman Ignacio Torres, Hernandez Silvia Fernandez filed Critical Consejo Superior Investigacion
Publication of WO2007003675A2 publication Critical patent/WO2007003675A2/fr
Publication of WO2007003675A3 publication Critical patent/WO2007003675A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)

Abstract

Ce modèle expérimental de neuro-inflammation est un animal transgénique caractérisé par ce qu'il exprime, exclusivement en astrocytes, une forme mutée de calcinerine exempte de la totalité ou d'une partie du domaine d'union de calmoduline et/ou du domaine auto-inhibiteur. Ce modèle animal peut servir à étudier et évaluer la progression des maladies neurodégénératives accompagnées d'une neuro-inflammation et d'altérations neurologiques pathologiques occasionnées par l'inflammation provoquant la mort neuronale et pour identifier des composés anti-inflammatoires, dont l'effet anti-inflammatoire est dû à une stimulation de la calcinerine astrocytaire.
PCT/ES2006/000387 2005-07-06 2006-07-05 Modele experimental de neuro-inflammation, procede d'obtention et applications WO2007003675A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501650A ES2289877B1 (es) 2005-07-06 2005-07-06 Modelo experimental de neuroinflamacion, procedimiento de obtencion y sus aplicaciones.
ESP200501650 2005-07-06

Publications (2)

Publication Number Publication Date
WO2007003675A2 WO2007003675A2 (fr) 2007-01-11
WO2007003675A3 true WO2007003675A3 (fr) 2007-04-26

Family

ID=37604829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000387 WO2007003675A2 (fr) 2005-07-06 2006-07-05 Modele experimental de neuro-inflammation, procede d'obtention et applications

Country Status (2)

Country Link
ES (1) ES2289877B1 (fr)
WO (1) WO2007003675A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035126A1 (fr) * 1995-05-03 1996-11-07 President And Fellows Of Harvard College Evaluation du role de la calcineurine en matiere d'immunosuppression et de neurotoxicite
WO2000009662A1 (fr) * 1998-08-17 2000-02-24 The Trustees Of Columbia University In The City Of New York Animal transgenique et ses utilisations pour l'identifier des composes utilises pour ameliorer la memoire a long terme
WO2003012093A2 (fr) * 2001-07-31 2003-02-13 Genopia Biomedical Gmbh Regulateur de la calcineurine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035126A1 (fr) * 1995-05-03 1996-11-07 President And Fellows Of Harvard College Evaluation du role de la calcineurine en matiere d'immunosuppression et de neurotoxicite
WO2000009662A1 (fr) * 1998-08-17 2000-02-24 The Trustees Of Columbia University In The City Of New York Animal transgenique et ses utilisations pour l'identifier des composes utilises pour ameliorer la memoire a long terme
WO2003012093A2 (fr) * 2001-07-31 2003-02-13 Genopia Biomedical Gmbh Regulateur de la calcineurine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CONBOY I.M. ET AL.: "calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions", PROC. ACAD. SCI. U.S.A., vol. 96, no. 11, 25 May 1999 (1999-05-25), pages 6324 - 6329, XP003010493 *
KAMINSKA B. ET AL.: "Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses", J. CELL MOL. MED., vol. 8, no. 1, 2004, pages 45 - 58, XP003010495 *
NORRIS C.M. ET AL.: "Calcineurin triggers reactive/inflammatory processes astrocytes and is upregulated in aging and Alzheimer's models", JOURNAL OF NEUROSCIENCE, vol. 25, no. 18, 4 May 2005 (2005-05-04), pages 4649 - 4658, XP003010491 *
PONS S. ET AL.: "Insulin-like growth factor-I stimulates dephosphorylation of ikappa B through the serine phosphatase calcineurin (protein phosphatase 2B)", J. BIOL. CHEM., vol. 275, no. 49, 8 December 2000 (2000-12-08), pages 38620 - 38625, XP003010494 *
SAYEN M.R. ET AL.: "Calcineurin transgenic mice have mitochondrical dysfunction and elevated superoxide production", AM. J. PHYSIOL. CELL PHYSIOL., vol. 284, no. 2, February 2003 (2003-02-01), pages C562 - C570, XP003010492 *
WINDER D.G. ET AL.: "Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin", CELL, vol. 92, no. 1, 9 January 1998 (1998-01-09), pages 25 - 37, XP002916706 *

Also Published As

Publication number Publication date
ES2289877B1 (es) 2008-12-01
WO2007003675A2 (fr) 2007-01-11
ES2289877A1 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
EE200600039A (et) Transgeenne loommudel patoloogilise ärevuse modelleerimiseks, meetod patoloogilisest ärevusest p?hjustatud haiguste v?i seisundite ravimiseks sobilike ühendite tuvastamiseks ja meetod Wfs1 valgu kasutamiseks sihtmärgina patoloogilise ärevuse vastase
WO2007142755A3 (fr) Analogues de la purine
WO2008115263A3 (fr) Inhibiteurs de la raf kinase contenant un fragment de liaison au zinc
DE602006001891D1 (de) Verfahren zur Herstellung von Fett oder Öl
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
WO2007059108A3 (fr) Quinolones substituees et procedes d'utilisation
DE602006011311D1 (de) Il-10 mutante
DE112005001805A5 (de) Mehrteilige Baugruppe aus metallischen Teilen und Verfahren zur Herstellung derselben
ATE510464T1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERBESSERUNG DER FUNKTIONALEN GEFÄßINTEGRITÄT, DES ÜBERLEBENS DER ZELLEN UND DER REDUCTION DER APOPTOSE NACH EINEM ISCHÄMIEANFALL IM GEHIRN
WO2007113172A3 (fr) Anticorps
ATE550293T1 (de) Getränkestromdrosselleitung und verfahren zur herstellung und montage derselben
WO2012017324A3 (fr) Composition pharmaceutique à combinaison et méthodes de traitement de maladies ou états associés à des maladies neurodégénératives
DE602006016199D1 (de) Nadellager mit einem Käfig und Verfahren zur Herstellung des Käfigs
EP2503341A3 (fr) Modulateurs de la régénération neuronale
WO2008121199A3 (fr) Modèles d'animaux transgéniques pour une maladie
WO2006039221A3 (fr) Inhibiteurs du transporteur de la glycine de piperidine de cyclopropyle
CN107428652A8 (zh) 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
EP4076422A4 (fr) Procédés d'atténuation de maladies et de troubles neurologiques
DE602006004387D1 (de) Verfahren zur Herstellung von Cycloalkanol und/oder Cycloalkanon
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
EP1802321A4 (fr) Compositions et procedes de modulation de pgc-1-alpha pour le traitement de maladies et de troubles neurologiques
CA2837895C (fr) Methodes de traitement ou de prevention de maladies neurologiques
WO2012145209A3 (fr) Agents anti-inflammatoires
WO2006079068A3 (fr) Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
WO2012071592A3 (fr) Animal transgénique humanisé

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06794060

Country of ref document: EP

Kind code of ref document: A2